Debevoise Advises Major Investor in Connection With the Sale of Envigo to Inotiv for Approximately $545 Million

23 September 2021

Debevoise & Plimpton LLP is advising a major investor in Envigo RMS Holding Corp. in connection with the sale of Envigo to Inotiv Inc. for a total transaction value of approximately $545 million. For more information, please see Envigo’s press release.

Envigo provides a broad range of standard research models to the pharmaceutical and biotechnology industries, government, academia, and other life science organizations. Inotiv is a leading contract research organization specializing in nonclinical and analytical drug discovery and development services.

The Debevoise team is led by M&A partner Andrew Bab and includes associate Katherine Durnan, finance counsel Gary Murphy, tax partner Gary Friedman and associate Robert Nelson-Sullivan, litigation partner Winston Paes, and antitrust partner Michael Schaper and counsel Kyra Bromley.